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An increase in clinical cases of Candidiosis globally as well as fungal resistance to drugs prompted the search for novel anti-Candida albicans agents
from plant sources. Leaf extracts ofMarkhamia obtusifoliawere screened for activity againstC. albicans in vitro. An acetone extract obtained following
serial exhaustive extraction contained mainly the active components with at least four active zones on the bioautogram. Bioassay guided fractionation of
this extract led to the isolation of three compounds which inhibited the growth of three C. albicans strains. Based on spectroscopy studies (NMR and
MS), the compounds were identified as 3β-hydroxyurs-12-en-28-oic acid, ursolic acid (1) 3β, 19α-dihydroxyurs-12-en-28-oic acid, pomolic acid
(2) and 2β, 3β, 19α -trihydroxy-urs-12-en-28-oic acid, 2-epi-tormentic acid (3). The most active compound was 3β, 19α-dihydroxy-12-ursen-28-oic
acid (2) with a minimum inhibitory concentration (MIC) value of 12.5 µg/mL forC. albicans isolated from dog and 25.0 µg/mL forC. albicans from cat
and ATCC 90028 at 24 h following incubation. However, at 48 h of incubationMICs were N400 µg/mL for all the three compounds isolated. This study
indicated thatM. obtusifolia could be a potential source of active principles against C. albicans.
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In recent times, there has been a rapid increase in fungal
infections globally and this could be attributed mainly to
increased susceptibility of individuals to infection due to
immunosuppression and invasive drug therapy (Schmidt-
Westhausen et al., 2004; Sims et al., 2005). Schwab et al.,
1997 reported the increased adherence of Candida albicans
to buccal epithelial cells obtained from AIDS patients compared
to non-sufferers. Multiple resistant phenotypes of C. albicans
have been found to coexist during episodes of oropharyngeal
candidiasis in AIDS patients (Lopez- Ribot et al., 1999).
C. albicans cells are protected by cell walls which mediate
interaction with the host for adhesion and modulation of
antifungal immune response in their host (Poulain and Jouault,
2004). Hence, the cell membrane may serve as a potential target
for antifungal drugs. The mechanism of action of some anti-⁎ Corresponding authors. Tel.: +27 12 529 8244; fax: +27 12 5298525.
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doi:10.1016/j.sajb.2009.07.003fungal drugs is by binding to the cell membrane of pathogenic
fungi in the presence of certain sterols, which subsequently
disturb permeability and transport characteristics of the
membrane, resulting in loss of intracellular cations (Katzung,
1984).
The current drugs available against Candida spp. include
Amphotericin b and fluconazole (Sandven, 2000).However, there
is an increasing rate of triazole resistance amongst C. albicans
isolates worldwide, which may be attributed to the frequent use
of triazoles as prophylaxis for fungal infections in AIDS patients
(Wroblewska et al., 2002). The situation is even worse in Africa
due to shortage of antifungal drugs, poverty and rise in the number
of HIV patients. In order to alleviate the problem of reduced
availability of drugs needed to treat candidiasis, traditional
medicine derived from plants are still being used in parts of Africa
(Motsei et al., 2003). This prompted the search for novel and
active anti-C. albicans agents from plant sources.
In a systematic search for bioactive secondary metabolites
from plant origin, Markhamia obtusifolia was selected for in-
vestigation as a result of our random screening of trees of
southern Africa for antifungal activity. M. obtusifolia is ats reserved.
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grows widely in southern and eastern Africa (Germishuizen and
Meyer, 2003). In folk medicine, roots ofM. obtusifolia are used
for the treatment of hookworm in parts of Tanzania (Chhabra
and Mahunnah, 1994) and there is no report of isolation of any
secondary metabolites from the plant. In this study, we report
the isolation and evaluation of anti-C. albicans compounds
from the leaves of M. obtusifolia.
2. Materials and methods
2.1. Plant materials
Fresh leaves of M. obtusifolia were harvested from the
Lowveld National Botanical Gardens Nelspruit, South Africa in
April 2005. The origin of the tree is recorded in the database of
the garden's herbarium with number 15/94. Leaves were dried
under shade at room temperature 27 °C for a period of one
month. The dried leaves were ground using a Jankel and Kunkel
Model A 10 mill into fine powder.
2.2. Extraction of plant material
Powdered leaf material (700 g) was subjected to serial
exhaustive extraction using 4 L each of hexane, dichloro-
methane, acetone and methanol in this order. Extraction was
repeated three times per extractant by replacing solvent after
each extraction. The third extraction for each solvent was left
overnight while shaking. The extracts obtained were filtered
under pressure and concentrated using a Büchi rotary
evaporator. The following yields were obtained per extractant;
Hexane (10.01 g, 1.43% w/w); dichloromethane (24.18 g,
3.45% w/w), acetone (21.03 g, 3% w/w) and methanol (19.2 g,
2.74% w/w).
2.3. Thin layer chromatography (TLC)
For each of the extracts obtained, 20mgwas dissolved in 2mL
of acetone and the mixture was homogenized using a sonicator to
obtain a solution of 10 mg/mL. Five micro litre of each solution
was spotted on TLC plates and components of the various extracts
were separated on normal phase silica gel TLC plates (Merck®).
Standard mobile phases (ethyl acetate:methanol:water (EMW),
10:1.35:1; benzene:ethyl acetate:ammonia (BEA), 18:2:0.2;
chloroform:ethyl acetate:formic acid (CEF), 10:8:2) were used
to separate components over a wide range of polarities. Some of
the developed chromatograms were examined under ultra violet
light at 254 and 354 nm (Camac Universal UV lamp TL 600) and
sprayed with vanillin–sulphuric acid reagent, while others were
kept for bioautography.
2.4. Bioautography
Three strains of C. albicans were used for this study. Two
strains were isolated from clinical cases of dogs and cats and
both provided to us by the Microbiology unit of the Department
of Veterinary Tropical Diseases, University of Pretoria. Thethird strain was standard ATCC 90028. The fungi were sub-
cultured on sabouraud dextrose agar (SDA) plates and kept
at 3 °C in a cold room until use. A sterile swap was used to
inoculate fungus into a liquid medium (sabouraud dextrose
broth). A final fungal concentration (106 cells/ml) used for this
study was determined by the aid of a Neubauer haemocyt-
ometer. The TLC plates were dried overnight next to a table fan,
and then sprayed with fungal suspension (actively growing cells
of C. albicans) using a spraying gun and incubated overnight
in a chamber at 38 °C and 100% RH. Plates were sprayed with
2 mg/mL solution of p-iodonitrotetrazolium (INT) (Sigma).
They were incubated for an hour and clear zones on the
bioautogram indicated inhibition of growth and an indication of
the bioactive components of the extracts. The retardation factor
(Rf) values of active components in the bioautograms were
noted and were targeted in bioassay guided fractionation.
2.5. Isolation of bioactive compounds
The acetone fraction (20 g) of M. obtusifolia leaves extract
obtained following serial exhaustive extraction was fractionated
on silica gel column and successively eluted with CHCl3 (100%)
followed by CHCl3:MeOH (95:5 v/v). Column fractions
collected in 50 mL test tubes were analysed on TLC plates.
The fractions were pooled into five groups (1, 2, 3, 4 and 5). TLC
analyses and bioautography results indicated that active
components of the fractions were distributed in group 5
(4.78 g). This fraction (group 5) was chromatographed on a
silica gel using CHCl3 (100%) followed by an increasing
gradient of EtOAc in CHCl3 up to 50%. Fractions were collected
in 50 mL test tubes and analysed on TLC plates. Based on TLC
analysis, tubes 56–89 contained single spots and were pooled
together. Evaporation of the solvent on a rotary evaporator
yielded compound 1 (white powder, 100 mg). Test tubes 104–
121 also contained a single spot on TLC, and evaporation of the
solvent yielded compound 2 (white powder, 75 mg). Compound
3 (White powder, 50 mg=1.05%) was obtained as a single spot
from test tubes 155–168 from the eluted column fractions. The
Rf values of the compounds in the CEF solvent system were:
0.826, 0.8 and 0.6 respectively.
2.6. Structure elucidation of compounds 1–3
Structure elucidations of the isolated compounds were carried
out using spectroscopic techniques: mass spectrometry, 1H and
13C NMR, DEPT together with 2D experiments (COSY, HMQC
and HMBC). Spectroscopic data of the compounds were also
compared with the appropriate literature. The spectra data agreed
with the reported data [Ursolic acid, 3β-hydroxyurs-12-en-28-oic
acid (1), (Seebacher et al., 2003; Thuong et al., 2005), Pomolic
acid, 3β, 19α-dihydroxy-urs-12-en-28-oic acid (2), (Cheng and
Cao, 1992), 2-epi-tormentic acid, 2β, 3β, 19α-trihydroxy-urs-12-
en-28-oic acid (3), (Delgado et al., 1989), Fig. 1]. The compounds
were identified as: 3β-hydroxyurs-12-en-28-oic acid (1), 3β,
19α-dihydroxy-urs-12-en-28-oic acid (2) and 2β, 3β, 19α-
trihydroxy-urs-12-en-28-oic acid (3) from their spectroscopic
data.
Table 1
Minimum inhibitory concentration (MIC) values of Markhamia obtusifolia
crude extracts at 24 h and 48 h.
Crude extracts MIC (mg/mL)
24 h 48 h
Hexane D N2.5 N2.5
C N2.5 N2.5
Q 1.25 N2.5
Dichloromethane D 0.16 N2.5
C 0.32 N2.5
Q 0.16 N2.5
Acetone D 0.16 N2.5
C 0.16 N2.5
C 0.8 N2.5
Methanol D 0.32 N2.5
C 0.32 N2.5
Q 1.25 N2.5
D indicates fungal isolate from dog, C indicates fungal isolate from cat and Q is
the standard isolate of C. albicans 90028.
Fig. 1. Structures of isolated compounds from Markhamia obtusifolia.
Table 2
Minimum inhibitory concentration (MIC) values of compounds 1–3 from
Markhamia obtusifolia at 24 h and 48 h.
Rf
values
MIC (µg/mL)
24 h 48 h
1 0.826 D 100 N400
C 50 N400
Q 50 N400
2 0.8 D 12.5 N400
C 25 N400
Q 25 N400
3 0.6 D 100 N400
C 100 N400
Q 50 N400
Positive control – 0.3125 0.3125
Negative control – No effect No effect
D indicates fungal isolate from dog, C indicates fungal isolate from cat and Q is
the standard isolate of C. albicans 90028. (Amphotericin b) was used as the
reference antibiotic and positive control.
56 F. Nchu et al. / South African Journal of Botany 76 (2010) 54–572.7. Microdilution assay (quantitative determination of anti-C.
albicans activity)
The microdilution method described by Eloff (1998a) was
employed with slight modifications in the determination of the
minimum inhibitory concentration (MIC) for the extracts and
compounds. Crude extracts (10 mg/mL), compounds 1–3
(1600 µg/mL) and Amphotericin b (160 µg/mL) were prepared
as stock solutions in acetone. One hundred microlitre of solution
containing crude extracts or pure compounds were serially
diluted 50% with water in 96-well microplates (two-fold serial
dilution). Fungal cultures were transferred into SDB, and 100 µL
of fungal concentration (106 cells/mL) was added to each well.
Amphotericin b was used as the reference antibiotic and positive
control. Solvent blank (acetone) was included as negative
control. Fortymicro litre of 0.2mg/mL of INT dissolved in water
was added to each microplate well and incubated at 37 °C 100%
RH (sealed in a plastic bag). TheMIC values were recorded after
24 and 48 h. The colourless tetrazolium salt acted as electron
acceptor and was reduced to a red coloured formazan product by
biologically active organisms (Eloff, 1998a). Experiments for
the MIC were carried out in replicate.
3. Results and discussion
Results obtained from this study indicated that the acetone
extract of M. obtusifolia was the most active compared to
extracts obtained with hexane, dichloromethane and methanol
following serial exhaustive extraction (Table 1). Acetone is a
very useful extractant in that it is less toxic, highly volatile and
capable of extracting a wide range of compounds from
lipophilic to hydrophilic compounds (Eloff, 1998b). The best
resolution of bioactive compounds was obtained in the CEF
solvent system, with at least four visible active spots in the
bioautograms. The bioautography results of the three strains
used were similar.Phytochemical investigation of the acetone fraction led to
isolation of three compounds: Ursolic acid, 3β-hydroxyurs-12-
en-28-oic acid (1), Pomolic acid, 3β, 19α-dihydroxy-urs-12-en-
28-oic acid (2), 2-epi-tormentic acid, 2β, 3β, 19α-trihydroxy-
urs-12-en-28-oic acid (3), which are active against C. albicans.
Compound (2) was the most active with an MIC value of
12.5 µg/mL at 24 h (Table 2). Ursolic acid had been isolated
from many plant species including Rosemarinus officialis,
Pyrus pyrifolia, Prunus domestica and Ocimum sanctum. The
compound exhibited potent anticancer potential in humans
through inhibition of signal transducers and activators of
transcription 3 (Pathak et al., 2007). Pomolic acid was
previously reported from Crysobalanus icaco by Fernandes
et al. (2003) and had been recently reported that it may be an
effective agent for the treatment of chronic myeloid leukaemia
(Vasconcelos et al., 2007). The compound, 2-epi-tormentic acid
was previously reported from Hoslundia opposite Vahl
(Ngadjui et al., 1995.) and had been reported to demonstrate
mild growth inhibition of M. tuberculosis (Wachter et al.,
1999).
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reading following the start of the experiment, however, the 48 h
reading indicated that there was no growth inhibition of C.
albicans by the extracts or pure compounds fromM. obtusifolia.
The standard C. albicans (ATCC 90028) was more susceptible
when compared with the isolates from dog and cat in most
instances during this study. Susceptibility to antifungal drugs
may vary with isolates. To the best of our knowledge no
previous report exists on the inhibitory effects of extracts of M.
obtusifolia and its isolated compounds on C. albicans. This
study demonstrated the importance of random screening of trees
for antifungal activity and potential of M. obtusifolia extracts
and isolated compounds in treatment of fungal infections.
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